Literature DB >> 2764651

Mild nephrotoxicity associated with vancomycin use.

N J Downs1, R E Neihart, J M Dolezal, G R Hodges.   

Abstract

Nephrotoxicity related to vancomycin hydrochloride therapy has been reported at overall rates of 7% to 16% and as high as 35% when combined with an aminoglycoside antibiotic. We conducted a prospective study in older men. A group that received vancomycin was compared with a control group to determine the incidence of nephrotoxicity secondary to vancomycin therapy alone and in combination with aminoglycosides, to identify possible risk factors associated with nephrotoxicity, and to determine the incidence of other adverse effects associated with vancomycin use. Nephrotoxicity occurred in 11 (17%) of 66 patients receiving vancomycin and in 3 (5%) of 57 controls overall. Stepwise logistic-regression analysis failed to identify underlying illnesses or concurrent risks that may have contributed to the development of nephrotoxicity associated with vancomycin. Adverse effects, including phlebitis (14%), neutropenia (1%), rash (0%), and red neck syndrome (0%), occurred at rates similar to previous reports.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2764651

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  20 in total

Review 1.  Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review.

Authors:  Sepideh Elyasi; Hossein Khalili; Simin Dashti-Khavidaki; Amirhooshang Mohammadpour
Journal:  Eur J Clin Pharmacol       Date:  2012-03-13       Impact factor: 2.953

2.  Effect of defibrillation threshold testing-induced ventricular fibrillation on renal function.

Authors:  John H Shin; Chotikorn Khunnawat; Jose Baez-Escudero; Bradley P Knight; John F Beshai
Journal:  J Interv Card Electrophysiol       Date:  2013-10-11       Impact factor: 1.900

Review 3.  Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations.

Authors:  K Mörike; M Schwab; U Klotz
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 4.  Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.

Authors:  C M Spencer; H M Bryson
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

5.  Comparative Study of Teicoplanin vs Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteraemia.

Authors:  C Y Liu; W S Lee; C P Fung; N C Cheng; C L Liu; S P Yang; S L Chen
Journal:  Clin Drug Investig       Date:  1996-08       Impact factor: 2.859

Review 6.  Pharmacokinetic optimisation of vancomycin therapy.

Authors:  W G Leader; M H Chandler; M Castiglia
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

7.  In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.

Authors:  T Lawrence; C Rotstein; T R Beam; E A Gorzynski; D Amsterdam
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 8.  Glycopeptides and nephrotoxicity.

Authors:  A W Chow; R M Azar
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

Review 9.  Teicoplanin: 10 years of clinical experience.

Authors:  M Trautmann; H Wiedeck; M Ruhnke; M Oethinger; R Marre
Journal:  Infection       Date:  1994 Nov-Dec       Impact factor: 3.553

10.  Vancomycin-Associated Nephrotoxicity: The Obesity Factor.

Authors:  Stephen W Davies; Jimmy T Efird; Christopher A Guidry; Zachary C Dietch; Rhett N Willis; Puja M Shah; Sara A Hennessy; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2015-09-01       Impact factor: 2.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.